Skip to content

Ulcerative Colitis Endoscopic Index of Severity and Fecal Calprotectin to Predict the Reaction to Corticosteroids of Acute Severe Ulcerative Colitis

Ulcerative Colitis Endoscopic Index of Severity and Fecal Calprotectin to Predict the Reaction to Corticosteroids of Acute Severe Ulcerative Colitis: A Prospective Observational Study

Status
UNKNOWN
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02922374
Enrollment
117
Registered
2016-10-04
Start date
2013-01-31
Completion date
2016-12-31
Last updated
2016-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Severe Colitis (ASC)

Keywords

acute severe colitis, corticosteroids, UCEIS, fecal calprotectin

Brief summary

For acute severe colitis (ASC) patients, corticosteroids (CS) was recommended as the first-line treatment in the guideline, but patients have a great risk of requiring colectomy or turning to second-line treatment. This study aim to verify the effectiveness of ulcerative colitis endoscopic index of severity(UCEIS) in predicting the reaction to corticosteroids, and explores the possibility that noninvasive marker fecal calprotectin (FC) could act as an alternative to UCEIS.

Interventions

DRUGcorticosteroids

Intravenous steroids were started with methylprednisolone 60 mg/d or hydrocortisone 400 mg/d for 3 days.

Sponsors

Jinling Hospital, China
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patients with a confirmed diagnosis of ASC according to Truelove and Witt's criteria; 2. Patients were generally able to tolerate the flexible colonoscopy before start of CS treatment;

Exclusion criteria

1. Patients with incomplete colonoscopy, inadequate fecal sample; 2. Patients with indeterminate diagnosis of ASC (colorectal cancer, Crohn's disease) according to colonoscopy; 3. Patients with infectious colitis, Clostridium difficile and CMV infection, primary immunodeficiency, recent history of immunosuppressant within 3 months. 4. Patients with bowel resection, intestinal anastomotic, and ileum enterostomy.

Design outcomes

Primary

MeasureTime frameDescription
stool frequency at day 33 daysThe response to intravenous steroid therapy was judged at day 3 according to Oxford criteria.
C-reactive protein (CRP) at day 33 daysThe response to intravenous steroid therapy was judged at day 3 according to Oxford criteria.

Secondary

MeasureTime frameDescription
ulcerative colitis endoscopic index of severity (UCEIS) before treatment3 daysThe UCEIS consists of the following three descriptors and was calculated as a simple sum: vascular pattern (scored 0-2), bleeding (scored 0-3), erosions and ulcers (scored 0-3).
Fecal Calprotectin before treatment3 daysFC was measured strictly with the instruction of the commercial test kits.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026